Clinical Trial: A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis

U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07765628) titled 'A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis' on Aug. 11.

Brief Summary: The primary objective of this study is to evaluate the efficacy of HS-20118 compared with placebo in participants with moderate to severe plaque psoriasis.

Study Start Date: Aug. 06

Study Type: INTERVENTIONAL

Condition: Moderate to Severe Plaque Psoriasis

Intervention: DRUG: HS-20118

Administered orally, once weekly (QW)

DRUG: Placebo

Administered orally, once weekly (QW)

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Published by HT D...